PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q1 2023. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $145,125 | – | 12,900 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,246,926 | $26,153,989 | 13.57% |
| venBio Partners LLC | 2,278,575 | $18,353,922 | 10.17% |
| Bain Capital Life Sciences Investors, LLC | 3,180,601 | $25,620 | 3.20% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 559,387 | $4,505,862 | 1.86% |
| 5AM Venture Management, LLC | 587,600 | $4,733,118 | 1.21% |
| Sio Capital Management, LLC | 228,385 | $1,839,641 | 0.91% |
| Novo Holdings A/S | 1,329,325 | $10,714,360 | 0.71% |
| Cormorant Asset Management, LP | 816,460 | $6,577 | 0.43% |
| Soleus Capital Management, L.P. | 336,900 | $2,713,730 | 0.28% |
| GENERAL ATLANTIC, L.P. | 2,420,155 | $19,494,349 | 0.23% |